Related references
Note: Only part of the references are listed.Targeting brain metastases in breast cancer
Chiara Corti et al.
CANCER TREATMENT REVIEWS (2022)
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
Min Yan et al.
LANCET ONCOLOGY (2022)
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
Naren Ramakrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Visualization and Analysis in the Field of Pan-Cancer Studies and Its Application in Breast Cancer Treatment
Xianwen Zhang et al.
FRONTIERS IN MEDICINE (2021)
Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases
Christine P. Carney et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2021)
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
Alice Indini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Patient-derived scaffolds influence secretion profiles in cancer cells mirroring clinical features and breast cancer subtypes
Emma Persson et al.
CELL COMMUNICATION AND SIGNALING (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular and cellular mechanisms underlying brain metastasis of breast cancer
Mari Hosonaga et al.
CANCER AND METASTASIS REVIEWS (2020)
A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019
Taylor McElroy et al.
ANTIOXIDANTS (2020)
Global Trends in Immunotherapy Research on Breast Cancer over the Past 10 Years
Soo Kyung Ahn et al.
JOURNAL OF ONCOLOGY (2020)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
T. Bachelot et al.
ANNALS OF ONCOLOGY (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Global trends in nanomedicine research on triple negative breast cancer: a bibliometric analysis
Ramon Handerson Gomes Teles et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Organotropism: new insights into molecular mechanisms of breast cancer metastasis
Wenjing Chen et al.
NPJ PRECISION ONCOLOGY (2018)
Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development
Anurag Saraf et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Trial sponsorship and self-reported conflicts of interest in breast cancer radiation therapy: An analysis of prospective clinical trials
Elton T. T. Leite et al.
BREAST (2017)
Assistive technology for people with dementia: an overview and bibliometric study
Ikram Asghar et al.
HEALTH INFORMATION AND LIBRARIES JOURNAL (2017)
Breast cancer brain metastases: biology and new clinical perspectives
Isabell Witzel et al.
BREAST CANCER RESEARCH (2016)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Naren Ramakrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model
Eun-Joo Park et al.
JOURNAL OF CONTROLLED RELEASE (2012)
A Perspective on Cancer Cell Metastasis
Christine L. Chaffer et al.
SCIENCE (2011)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Genes that mediate breast cancer metastasis to the brain
Paula D. Bos et al.
NATURE (2009)
Sites of Distant Recurrence and Clinical Outcomes in Patients With Metastatic Triple-negative Breast Cancer High Incidence of Central Nervous System Metastases
Nancy U. Lin et al.
CANCER (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
HJ Burstein et al.
ANNALS OF ONCOLOGY (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
C Christodoulou et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial
E Verger et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Share Paper
